Radionuclide therapy effective in high-grade neuroendocrine neoplasms

(Society of Nuclear Medicine and Molecular Imaging) Peptide receptor radionuclide therapy (PRRT) has been shown to be safe and effective for patients with grade 3 (G3) neuroendocrine neoplasms (NENs), according to research presented at the Society of Nuclear Medicine and Molecular Imaging's (SNMMI) 66th Annual Meeting.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news